Veloxis Pharmaceuticals, an Ashai Kasei company, today announced dosing of the first patient by its partner, Xenikos, in a global pivotal Phase 3...
NIJMEGEN, The Netherlands, June 27, 2022 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, today announced enrollment of the first patient in a global pivotal Phase 3 clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT).
Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune diseases and post-transplant rejection, today announced the appointment of Hassan Aly, MD, PhD, as Chief Medical Officer. Dr. Aly brings over three decades of practice in the treatment of hematological malignancies, including allogeneic hematopoietic stem cell transplantation (HSCT) and 10 years of experience in the clinical development of drugs for leukemia, lymphoma and myeloma patients. In his role at Xenikos, he will provide medical input and oversight on the Company’s clinical and regulatory development strategy and execution, including assessing and interpreting the clinical safety data of the Phase 3 study evaluating T-Guard® for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD).